Lung Diseases Cies Search Engine [selected websites]

Loading

Blog Archive

Feb 26, 2008

GlaxoSmithKline, EMEA positive opinion for the approval of Hycamtin® (topotecan) hard capsules for the treatment of relapsed small cell lung cancer

04 February 2008 - GlaxoSmithKline (GSK) announced that oral Hycamtin (topotecan hard capsules) has received a positive opinion from the European Medicines Agency (EMEA) recommending marketing authorisation. GSK expects final approval by the European Commission and Marketing Authorisation for this indication in approximately two months. Topotecan capsules will be indicated as monotherapy for the treatment of adult patients with relapsed small cell lung cancer (SCLC) for whom re-treatment with the first-line regimen is not considered appropriate...GlaxoSmithKline's Press Release-